Shares of OneSource Specialty Pharma Ltd. fell 1.59% to ₹1,646.40 on the NSE as of 11:37 am on Tuesday, following the announcement of the strategic manufacturing partnership. The stock has declined nearly 18% over the past year and is currently trading at a total market capitalisation of approximately ₹18,856 crore. According to The Hindu BusinessLine, the market reaction suggests investors are weighing the strategic benefits against potential near-term execution challenges in scaling the manufacturing partnership. The stock has touched a 52-week high of ₹2,088 in July 2025 and a low of ₹1,057 in January 2026, reflecting the volatility around this major strategic development.
OneSource Specialty Pharma and Formycon AG, an independent biosimilar developer headquartered in Munich, announced a strategic manufacturing partnership for biosimilars on July 14, 2026. According to reports from The Hindu BusinessLine, the collaboration brings together Formycon's biosimilar development excellence with OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets. The partnership reflects the shared commitment of both companies to advancing global access to biosimilars through scalable, high-quality and cost-efficient manufacturing. As per CNBC TV18, Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, emphasized that the partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide.
Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics' facility in Bangalore. The Bengaluru hub acts as the primary manufacturing site for both drug substance and drug product, with high-volume mammalian capacity up to 20,000L serving as a critical differentiator. This manufacturing arrangement leverages OneSource's established biologics infrastructure to support Formycon's global biosimilar development initiatives, with the partnership expected to drive a sustained 15-20% increase in capacity utilization over the next two fiscal years. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
The partnership secures long-term manufacturing rights for 5 biosimilars, with the collaboration increasing OneSource's exposure to the European biosimilar market via Formycon's portfolio. According to recent reports, this deal builds high-margin recurring revenue and improves overall EBITDA visibility for the company. The global biosimilar market is projected to reach $75 billion by 2030, with Formycon's focus on ophthalmology and immunology biosimilars representing a high-growth client opportunity. Formycon currently has three biosimilars on the market including FYB201/ranibizumab, FYB202/ustekinumab and FYB203/aflibercept, with four pipeline candidates currently in development including FYB206/pembrolizumab and FYB208/dupilumab. The partnership positions OneSource to capitalize on the growing biosimilar market opportunities while leveraging their respective expertise in biologics development and manufacturing capabilities.
The collaboration validates OneSource's recently consolidated assets under the ONESOURCE brand, following the operational merger of Stelis Biopharma and Steriscience in late 2025. In early 2026, the company reported 20% year-on-year growth in its order book, driven by mid-sized European biotech firms. The partnership is expected to drive a 15% capacity utilization boost over the next 18 months, with the company recently receiving green-channel clearance for its new export-oriented unit (EOU) in Bengaluru. Formycon Chief Executive Officer Dr. Stefan Glombitza emphasized that the tie-up aligns with the company's FYB4Growth strategy, stating that reliable, scalable and cost-efficient manufacturing is a cornerstone of their strategy. Neeraj Sharma, Managing Director & CEO of OneSource, highlighted that India is uniquely positioned to serve as a global hub for world-class biologics, while the deal effectively derisking OneSource's growth trajectory by anchoring capacity to a proven global pipeline.
